Anemia Pharm Flashcards

1
Q

What molecules make up heme?

A

protoporphyrin IX and Fe

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Causes of microcytic anemia

A

reduced iron availability, reduced heme synthesis, reduced globin production, rare disorders

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Foods from which iron is easily absorbed

A

meat, fish, poultry

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

How does food effect iron absorption?

A

inhibits absorption

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Side effects of oral iron tablets

A

nausea, constipation, anorexia, heartburn, vomiting, diarrhea, dark stools

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

IV iron complexes

A

iron dextran, sodium ferric gluconate, iron-sucrose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Acute iron toxicity

A

lethal in young children; sxs include necrotizing gastroenteritis with vomiting, abd pain, bloody diarrhea

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Treatment of acute iron toxicity

A

parenteral deferoxamine, and whole bowel irrigation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Chronic iron toxicity

A

iron deposits in heart, liver, pancreas and causes organ failure and death

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Sources of vitamin B12

A

fish, meat, poultry, eggs, milk, milk products, fortified breakfast cereals

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

How long does it take to develop a vitamin B12 deficiency?

A

years, liver stores a significant amount

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Neurological sxs of B12 deficiency

A

paresthesias, weakness, spasticity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

How is cobalamin released from food

A

acid and pepsin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Causes of pernicious anemia

A

ab formation blocking IF interaction with cobalamin, chronic atrophic gastritis, gastrectomy, H. pylori infection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Sxs of B12 deficiency

A

vitiligo, hyperpigmentation, glossitis, anemia, neutropenia, thrombocytopenia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Treatment of vitamin B12 dficiency

A

oral B12, initially 1-2mg/day for 2 weeks, then 1mg daily; parental therapy if neuro sxs are present

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Sources of folate

A

yeast, liver, kidney, green leafy vegetables

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Where is folate absorbed in the body?

A

jejunum

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

How long does it take to develop a folate deficiency?

A

three weeks without adequate intake

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Sxs of folate deficiency

A

neural tube defect in fetus, jaundice, mouth ulcers, anemia, neutropenia, thrombocytopenia, depression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Treatment of folate deficiency

A

oral folate, 1mg/day for 4 months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

epoetin alfa MOA

A

contains a.a. sequence of isolated erythropoeitin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

epoeitn alfa effects

A

stimulates erythropoiesis, increase rtc in 10 days, increase RBC 2-6 weeks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Clinical applications epoetin alfa

A

chronic kidney disease, CA chemo

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Pharmacokinetics of epoetin alfa
IV or subcutaneously; t1/2 = 4-13 hrs
26
Epoetin alfa toxicities
increased risk of death, MI, stroke, VTE, tumor progressoin
27
Hydroxyurea MOA
boosts level of hgb
28
Effects of hydroxyurea
lowers concentration of HbS within a cell
29
Clinical applications hydroxyurea
sickle cell
30
Pharmacokinetics hydroxyurea
administered orally, distributed widely
31
Toxicities hydroxyurea
neutropenia, anemia, oral ulcers, mild GI upset, hyperpigmentation, rash, nail changes
32
Eculizumab MOA
mab binds to C5, inhibits cleavage, preventing generation of complement complex
33
Eculizumab effects
inhibits terminal complement mediated intravascular hemolysis, inhibits complement mediated thrombotic microangiopathy
34
Clinical applications eculizumab
PNH, atypical HUS
35
Pharmacokinetics eculizumab
IV over 35 min oncer per week for 4 weeks, maintenance doses given IV every 2 weeks
36
Toxicities of eculizumab
viral infections, life-threatening meningococal infections, immunogenic, URI, msk pain, anemia, leukopenia, HTN, HA
37
Causes of neutropenia
cancer, congenital disorders, viral infections, autoimmune disorders, overwhelming infections, drugs
38
Sxs of neutropenia
low-grade fever, sore mouth, odynophagia, gingival pain and swelling, skin abscesses, recurrent sinusitis and otitis, sxs of pneumonia, perirectal pain and irritation
39
Filgrastim MOA
human G-CSF
40
Filgrastim effects
regulates production of neutrophils within bone marrow
41
Clinical applications filgrastim
decrease incidence of infection in pts with nonmyeloid malignancies receiving myelosuppressive anticancer drugs or those receiving bone marrow transplant, mobilize hematopoietic progenitor cells
42
Pharmacokinetics filgrastim
IV infusion or continuous SC infusion, wait 24 hrs after chemo, dividing cells most vulnerable
43
Filgrastim toxicities
allergic rxn, bone pain
44
sargramostim MOA
recombinant form of GM-CSF
45
Effects sargramostim
increase production neutrophils, eosinophils, monocytes and macrophages
46
Clinical applications sargramostim
accelerate recovery myeloid cells after autologous bone marrow transplant, mobilize hematopoietic stem cells, used after chemo induction in pts with AML
47
Pharmacokinetics sargramostim
given IV or SC
48
Toxicities sargramostim
edema, sequestration of granulocytes in pulm circulation causing dyspnea, worsened pre-existing renal and hepatic dysfx, can cause fatal gasping syndrome
49
Does filgrastim or sargramostim have fewer side effects?
filgrastim
50
UpToDate recommendations on CSF use in CA
no role in afebrile patients, primary prophylaxis if incidence of febrile neutropenia is >20%, secondary prophylaxis if it would reduce efficacy of chemo
51
Plerixafor MOA
partial agonist of CXCR4 receptor, homing to HSC
52
Plerixafor effects
mobilizes HSC to plasma
53
Plerixafor clinical use
used in pts who do not mobilize sufficient stem cells for transplant with just G-CSF
54
Plerixafor pharmacokinetics
subcutaneous injection, 3-5 hr half life
55
Toxicities plerixafor
hypersensitivity rxn
56
Oprelvekin MOA
IL-11
57
Effects oprelvekin
promote formation and maturation of megakaryocytes
58
Clinical applications oprelvekin
can be used to treat thrombocytopenia in pts undergoing myelosuppressive chemo for non-myeloid CA
59
Pharmacokinetics oprelvekin
given SC once/day, half life 7 hrs
60
Toxicities oprelvekin
significant edema, cardiac dysrhythmias, severe allergic rxn, bloodshot eyes
61
Romiplostim MOA
binds to TPO receptor
62
Romiplostim effects
increase plt count in healthy individuals, people with ITP, or those with myelodisplastic syndrome
63
Romiplostim clinical applications
ITP, after failure of glucocorticoids
64
Pharmacokinetics romiplostim
administered weekly as a SC injection, half life 3.4 days
65
Toxicity romiplostim
well-tolerated, but may have allergic rxn
66
Eltrombopag MOA
non-peptide TPO receptor agonist
67
Eltrombopag effects
increase plt ct
68
Clinical applications eltrombopag
excess plt destruction due to ITP, cirrhosis due to hepatitis C
69
Pharmacokinetics eltrombopag
orally active, given once/day, half life 21-36 hrs
70
Toxicity eltrombopag
hepatotoxicity